RadnostixINIS +2.73% PB Ratio is 14.38 as of Jun. 27, 2026, which is 55% above its 10-year median of 9.29. The stock has 3 warning signs investors should review. Among 922 Drug Manufacturers companies, Radnostix ranks worse than 89.37% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-27), Radnostix's share price is $0.07191. Radnostix's Book Value per Share for the quarter that ended in Mar. 2026 was $0.01. Hence, Radnostix's PB Ratio of today is 14.38.
The historical rank and industry rank for Radnostix's PB Ratio or its related term are showing as below:
INIS'
s PB Ratio Range Over the Past 10 Years
Min: 3.44 Med: 9.29 Max: 175
Current: 14.38
During the past 13 years, Radnostix's highest PB Ratio was 175.00. The lowest was 3.44. And the median was 9.29.
INIS's PB Ratio is ranked worse than 89.37% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.825
vs INIS: 14.38
During the past 12 months, Radnostix's average Book Value Per Share Growth Rate was -37.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -4.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 37.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Radnostix was 260.20% per year. The lowest was -32.50% per year. And the median was 11.90% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Radnostix PB Ratio Related Terms
Radnostix PB Ratio Historical Data
* Premium members only.
The historical data trend for Radnostix's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Radnostix's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Radnostix PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Radnostix's PB Ratio distribution charts can be found below:
* The bar in red indicates where Radnostix's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Radnostix's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Radnostix (INIS) has a PB Ratio of 14.38 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Radnostix and its competitors. This is 55% above median its historical median of 9.29. Over the past decade, Radnostix's PB Ratio has ranged from 3.44 to 175.00. According to the industry distribution chart, Radnostix ranks #824 out of 922 companies in the Drug Manufacturers industry, placing it in the top 89.4%.
Is Radnostix's PB Ratio too high?
Radnostix's current PB Ratio of 14.38 is 55% above median its 10-year median of 9.29. Over the past 10 years, this metric has ranged from a low of 3.44 to a high of 175.00. The Drug Manufacturers industry median PB Ratio is 1.83. Radnostix's value of 14.38 is 687.9% above this industry median. Based on the distribution chart, Radnostix ranks #824 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Radnostix's PB Ratio compare to TLPH and IXHL?
According to the Drug Manufacturers industry distribution chart, Radnostix ranks #824 out of 922 companies for PB Ratio. This places Radnostix in the lower half of its industry. The industry median PB Ratio is 1.83. Radnostix's value of 14.38 is 687.9% above this benchmark. Historically, Radnostix's own PB Ratio has ranged from 3.44 to 175.00 over the past decade. While the company's 10-year median is 9.29 vs. the industry median of 1.83, Radnostix has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.83, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Radnostix's current PB Ratio of 14.38 is 687.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Radnostix and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Radnostix's current PB Ratio is 14.38, which is 55% above median its own 10-year median of 9.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radnostix stock overvalued right now?
Based on GuruFocus' analysis, Radnostix (INIS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.07 — trading 43.8% above its estimated fair value. The current PB Ratio is 14.38, which is 55% above median its 10-year median of 9.29 and 687.9% above the Drug Manufacturers industry median of 1.83. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Radnostix (INIS), the current PB Ratio is 14.38 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Radnostix Inc manufactures a wide range of radioisotope-focused products used in a variety of medical and industrial applications. The company produces generic sodium iodide I-131 drug product, produces a variety of cobalt-60 products, and is in development to manufacture and sell medical devices for the nuclear medicine industry. Its business consists of five reportable segments, which include: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products. The majority of the revenue is derived from the Theranostics Products segment, which produces and distributes various isotopically pure radiopharmaceuticals, APIs, and radiochemicals for medical, industrial, and research applications.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INIS has been successfully added to your 